VC  KBL Healthcare Ventures

http://www.kblvc.com





     Office Locations:

150 West 56th Street Suite 5901
New York, NY 10019
Phone: 212-319-5555
Fax: 212-319-5591

 

Stages:

  • Early
  • Growth


 

Industries:

  • Life Sciences & Healthcare
  • Medical Device

  •  

    Description:

    KBL is a venture capital firm dedicated to investing in early stage and emerging growth healthcare companies. The firm's goal is to identify companies that are run by seasoned management teams and that have the potential to create long term value. Major areas of investment include life sciences, medical devices, healthcare services and medical information technology. Within the life sciences space, KBL will invest in biopharmaceuticals, drug discovery platforms and advanced materials. Within the medical device area, KBL seeks companies addressing large, unmet medical needs with demonstrated clinical benefit. In July 2007, KBL completed a $138 million IPO led by Citi to target a merger with a healthcare or healthcare-related business. KBL Merger Corp. IV completed its IPO in June 2017, raising $115 million with the goal of identifying and acquiring a company with a strong value proposition mainly in the U.S. healthcare or the healthcare-related wellness industry.



    Investment Firm Key

       VC = Venture Capital
       PE = Private Equity
       A = Angel
       I = Incubator
       MB = Merchant Bank
       VD = Venture Debt
       FI = Family Investment Office
       FOF = Fund of Funds
       ED = Economic Development Office   
       TT = Technology Transfer Office
       CVC = Corporate Venture Capital
       SEC = Secondary Purchaser
       HF = Hedge Fund/Mutual Fund
       
       
       
    COMPANY STAGEREVENUE
    Venture Capital
    Seed Stage
    (includes "pre-seed," or
    concept stage)
    No Revenue
    Early StageMinimal
    Revenue
    Growth Stage
    (also called Mid-stage)
    $2M-$7M
    Expansion Stage
    (also called Late-stage)
    $7M and greater
    Private Equity
    Lower Middle Market$10M-$249M
    Middle Market$250M-$499M
    Upper Middle Market$500M-$1B
    Large Cap>$1B
       
       
     

    Investment Team:


    Name   Title
    Get the complete investment team + individual email addresses for investment team partners. Get personal images, LinkedIn links, investment specialties, office locations and more with a National Database subscription or New York Database subscription.
    Joseph Williamson COO and Director
    Marlene Krauss M.D. Director and Chief Executive Officer

     

    Portfolio companies include:


      Neuronetics
        web link


     

    Recent News: